Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Modulating the Vaginal Microbiome after Implantation Failure
2018-002376-41Phase 4Completed
- Sponsor
- Zealand University Hospital
- Start
- Aug 2018
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in Vaginal dysbiosis, Endometrial microbiome and bacterial vaginosis (BV) comparing Vivag Plus with Placebo (2 arms). Primary endpoint: Primary microbiome change and stability endpoint. Started Aug 2018; status: completed.
02
Drugs
EcoVag
03
Conditions
Vaginal dysbiosisEndometrial microbiomebacterial vaginosis (BV)
Beyond the preview
Go deeper on 2018-002376-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002376-41.